Drs Lyle, Ammash, and McLeod discuss risk stratification for stroke in adults with complex congenital heart disease and how to choose between warfarin or the direct oral anticoagulants in the absence of data.

Dr Mandrola gets the details on the PCSK9 inhibitor evolocumab, and asks the $64,000 (or is that $14,000) question about cost-effectiveness.

If Dr Walton-Shirley were designing the next trial on PCSK9 inhibitors, she'd include a Mediterranean diet and exercise arm. She and Dr Mandrola ponder alternative uses of our healthcare dollars.

2017 American College of Cardiology (ACC) sessions in review: PCSK9 inhibitors, bioresorbable stents, CTO-PCI procedures, subclinical leaflet thrombosis in tissue aortic valves, and NOACs feature.

Drs Harrington and Yancy review the efficacy and cognitive safety data for the PCSK9 inhibitor evolocumab, presented at the American College of Cardiology sessions.

A post-PCI bleeding risk score, BMI and AF ablation, nonalcoholic fatty liver disease, sugary drinks, and upcoming studies at ACC are discussed in this week's podcast.

Statins poststroke, advance directives, sleep disorders and ICD shocks, genetic test to gauge statin benefit, and NOACs in valvular disease are discussed by Dr John Mandrola in this week's podcast.

The Veterans Health Administration is the largest integrated healthcare system in the US with a common EHR. Dr Harrington learns the advantages for cardiology practice and research.

New cardio drugs, such as PCSK9 inhibitors and the angiotensin receptor neprilysin inhibitor, are expensive. Dr O'Donoghue asks whether that should affect guideline recommendations.

AF progression, alcohol and CV risk, embolic protection during TAVR, hydration to prevent contrast-induced nephropathy, and MRI in patients with cardiac devices are discussed in this week's podcast.